PPT-Patient Selection for PARP

Inhibitors Purpose and Practicalities Presenter Charlie Gourley MBChB PhD FRCP Professor of Medical Oncology University of Edinburgh Edinburgh Scotland United Kingdom Topics for Discussion. When the patient recruitment decision is influenced by the knowledge of upcoming treatment allocation selection bias is inevitable and the validity of the trial result is seriously damaged Allocation concealment is defined as the procedure for prote 1 1 GENERAL APPLICATION AND SELECTION OF THE FLEX-HONE Practical Hosiery. The use of compression hosiery is widespread, but there is wide variation in almost every aspect of selection and prescribing practice. Also, there are hundreds of types . There are different classes – different testing standards (RAL; British Standards). Knowledge Network. Accelerate . cancer R&D. By efficiently searching for treatments and cures. By learning from . every. patient both retrospectively and prospectively. By shattering the silos to share . Opinion. 55 year-old woman with . recurrent . ovarian cancer. Underwent an optimal . cytoreductive. surgery and placement of an intraperitoneal catheter. Disease progressed through multiple lines of chemotherapy. and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Niraparib. and . Temozolomide. in Patients with Previously Treated, incurable Ewing Sarcoma . Co-Principal Investigators: . Sandra . Strauss, MD, PhD. University College London. Rashmi. . Chugh. , MD. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. Program Overview . Discussion Outline. DNA Repair. ABCs of DNA Repair. DNA Repair Defects in Cancer. DNA Repair Defects Can Be an Achilles' Heel. Synthetic Lethality and Cancer DNA Repair Defects. Increased Sensitivity of . actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Mansoor Raza Mirza. NSGO: Nordic Society of Gynaecological Oncology. Five-year . survival. 15%. 30%. 40%. ?50%?. First use . of . cisplatin. First use . of . carboplatin. First use . of . Paclitaxel . First reports . of. bevacizumab. Positive evidence . for weekly paclitaxel in first line. IAGNOSIS Benign chronic condition with minimal objective findings or no definite medical diagnosis. Examples: fibromyalgia, migraine headaches, non-specific back pain. ondition concordant with moderat Infectious Diseases. Courses in Therapeutics and Disease State Management. Learning Objectives (Slide 1 of 3). Recognize general signs, symptoms, laboratory, and microbiologic findings of a patient with an infection.